Skip to Content

'
Betul Oran, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Unrelated Donor Program, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit 0423
Unit Number: 423
Houston, TX 77030
Room Number: FC5.2018

Education & Training

Degree-Granting Education

2004 Boston University School of Public Health, Boston, MA, MS, Epidemiology
1995 Hacettepe University, Ankara, Turkey, MD, Medicine

Postgraduate Training

6/2011-11/2011 Oncology Fellowship, Hacettepe, Ankara, Turkey
1/2006-2/2008 Internal Medicine Residency, Boston University, Boston, MA
11/2004-11/2005 Blood and Marrow Transplantation Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
11/2001-11/2004 Hematology and Oncology Fellowship, Boston University, Boston, MA

Board Certifications

2011 American Board of Hematology
2009 American Board of Internal Medicine
2001 Turkish Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/24/2013. PMID: 23345254.
2. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 3/2013. e-Pub 1/18/2013. PMID: 23330820.
3. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2/2013. e-Pub 9/13/2012. PMID: 22982533.
4. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. NIHMSID: NIHMS430109.
5. Oran B, Weisdorf DG. Survival for older patients with AML: a population based study. Haematologica. e-Pub 7/2012. PMCID: PMC3590098.
6. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 47(4):494-8, 4/2012. e-Pub 5/23/2011. PMID: 21602900.
7. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 17(9):1327-34, 9/2011. e-Pub 1/11/2011. PMID: 21232621.
8. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17(7):1025-32, 7/2011. e-Pub 11/1/2010. PMID: 21047561.
9. McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 35(6):757-61, 6/2011. e-Pub 1/2011. PMID: 21232793.
10. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 17(3):356-64, 3/2011. e-Pub 5/2010. PMID: 20553926.
11. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant 45(1):21-4, 1/2010. e-Pub 5/2009. PMCID: PMC3672063.
12. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 5/2009. PMID: 19361753.
13. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 5/2009. e-Pub 11/17/2008. PMID: 19011667.
14. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid 16(2):103-7, 2009. PMCID: PMC2911629.
15. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 12/2007. e-Pub 7/5/2007. PMID: 17611563.
16. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 4/2007. e-Pub 2/8/2007. PMID: 17382251.
17. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 4/2007. e-Pub 2/2007. PMID: 17382253.
18. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108(12):3945-7, 12/1/2006. e-Pub 8/22/2006. PMCID: PMC1895463.
19. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4):299-303, 8/2006. e-Pub 7/3/2006. PMID: 16819437.
20. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 35(6):567-75, 3/2005. PMID: 15665842.
21. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15(11):1622-6, 11/2004. PMID: 15520062.
22. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92(4):747-51, 10/2004. PMID: 15467905.
23. Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol 21(1):31-40, 2004. PMID: 15034211.
24. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 74(2):131-5, 10/2003. PMID: 14508801.
25. Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, Ozcebe O, Dundar S, Kirazli S. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost 7(2):126-30, 4/2001. PMID: 11292190.

Invited Articles

1. Oran B. Can double-cord transplants provide a more potent graft-vs-leukemia effect? Best Pract Res Clin Haematol 25(4):479-82, 12/2012. e-Pub 11/2012. PMID: 23200545.
2. Oran B, Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012:215-22, 2012. PMID: 23233584.
3. Oran B, Weisdorf DJ. Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 18(6):395-400, 11/2011. NIHMSID: NIHMS348482.
4. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 18(6):388-94, 11/2011. PMID: 21897227.

Last updated: 7/31/2014